AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21279863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (14 ± 1 °C)
Number of subjects: 14
Study 21279863 — intervention group
Group type: COMPARATOR
Intervention: Tepid water immersion (28 ± 1 °C)
Number of subjects: 14
Study 19038563 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase 0.58 mg/kg once-weekly intravenous infusion
Number of subjects: 33
Study 19038563 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase 1.2 mg/kg every 2 weeks
Number of subjects: 33
Study 19038563 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase 1.2 mg/kg every week
Number of subjects: 33
Study 19038563 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase 1.8 mg/kg every 2 weeks
Number of subjects: 33
Study 19038563 — intervention group
Group type: COMPARATOR
Intervention: All dose regimens
Number of subjects: 33
Study 16908343 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 nm-wavelength diode laser
Number of subjects: 0
Study 16908343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064 nm-wavelength neodymium:yttrium-aluminum-garnet laser
Number of subjects: 0
Study 14962687 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 60
Study 14962687 — intervention group
Group type: COMPARATOR
Intervention: Non-fat cow milk
Number of subjects: 60
Study 11944733 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosiphon grandiflorus (OG) tea, 2 cups daily (2.5 g dry wt per tea bag)
Number of subjects: 48
Study 11944733 — intervention group
Group type: COMPARATOR
Intervention: Sodium potassium citrate (SPC), 5-10 g in solution divided into three times a day
Number of subjects: 48
Study 11944733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (G1 and G2)
Number of subjects: 48
Study 11944733 — intervention group
Group type: COMPARATOR
Intervention: Sodium potassium citrate (SPC)
Number of subjects: 48
Study 9598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (5 and 10 ppm for two hours)
Number of subjects: 27
Study 9598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Number of subjects: 27
Study 9598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning + Almitrine (16 mg.kg-1.min-1)
Number of subjects: 27
Study 9598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide + Almitrine
Number of subjects: 27
Study 9598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide + Prone positioning
Number of subjects: 27
Study 9598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide + Prone positioning + Almitrine
Number of subjects: 27
Study 9598253 — intervention group
Group type: COMPARATOR
Intervention: Control (no further inhalation after initial NO)
Number of subjects: 27
Study 9598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 27
Study 7931927 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention with multi-media prompts
Number of subjects: 0
Study 7931927 — intervention group
Group type: COMPARATOR
Intervention: Multi-media intervention without prompts
Number of subjects: 0
Study 3280493 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 260
Study 3280493 — intervention group
Group type: COMPARATOR
Intervention: No antihypertensive treatment (Control)
Number of subjects: 260
Study 3280493 — intervention group
Group type: COMPARATOR
Intervention: General population (Control)
Number of subjects: 260
Study 29570044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo
Number of subjects: 948
Study 29570044 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase placebo plus active oral aspirin dose of 325 mg
Number of subjects: 948
Study 27177263 — intervention group
Group type: EXPERIMENTAL
Intervention: Convective warming with an underbody blanket
Number of subjects: 60
Study 27177263 — intervention group
Group type: COMPARATOR
Intervention: Conductive warming with an underbody mattress and additional warming of the legs
Number of subjects: 60
Study 25741816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 125 μg
Number of subjects: 652
Study 25741816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 24002278 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC-based strategy (n=1002) containing either (1) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide
Number of subjects: 2004
Study 24002278 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=1002)
Number of subjects: 2004
Study 21558462 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (90 mg vaginally) from 24 to 34 weeks of pregnancy
Number of subjects: 0
Study 21558462 — intervention group
Group type: COMPARATOR
Intervention: Placebo from 24 to 34 weeks of pregnancy
Number of subjects: 0
Study 18499565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination-facilitated PCI (abciximab plus half-dose reteplase)
Number of subjects: 2452
Study 18499565 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab-facilitated PCI
Number of subjects: 2452
Study 18499565 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI (abciximab administered immediately before the procedure)
Number of subjects: 2452
Study 18499565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination-facilitated PCI
Number of subjects: 2452
Study 18499565 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 2452
Study 16575661 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate defect coverage with a pedicled muscle flap (group A)
Number of subjects: 16
Study 16575661 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-assisted closure (V.A.C.)-therapy (group B)
Number of subjects: 16
Study 12675460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof‐Lex disks
Number of subjects: 40
Study 12675460 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond paste
Number of subjects: 40
Study 12675460 — intervention group
Group type: COMPARATOR
Intervention: White silicon and black rubber
Number of subjects: 40
Study 12675460 — intervention group
Group type: COMPARATOR
Intervention: Shofu rubbers
Number of subjects: 40
Study 12675460 — intervention group
Group type: COMPARATOR
Intervention: Diamond burs
Number of subjects: 40
Study 10759437 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 14
Study 10759437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8931286 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously ventilated hood system
Number of subjects: 5
Study 8931286 — intervention group
Group type: COMPARATOR
Intervention: Demand valve system with oral-nasal mask
Number of subjects: 5
Study 1304176 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl/MFP dentifrice
Number of subjects: 41
Study 1304176 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 41
Study 30614406 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week resistance training programme
Number of subjects: 30
Study 30614406 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily routines)
Number of subjects: 30
Study 28917549 — intervention group
Group type: EXPERIMENTAL
Intervention: Written, verbally performed, preintubation checklist
Number of subjects: 262
Study 28917549 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no preintubation checklist)
Number of subjects: 262
Study 27456910 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed endurance exercise (S)
Number of subjects: 17
Study 27456910 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed endurance followed by endurance exercise (S + E)
Number of subjects: 17
Study 27456910 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise (E)
Number of subjects: 17
Study 24684977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep medication (melatonin 14%, clonidine 9%)
Number of subjects: 257
Study 24684977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep medication use
Number of subjects: 257
Study 19959684 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued drinking (average of 2.3 drinks/d) postdiagnosis
Number of subjects: 264
Study 19959684 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued smoking postdiagnosis
Number of subjects: 264
Study 19959684 — intervention group
Group type: COMPARATOR
Intervention: Smoking history before diagnosis
Number of subjects: 264
Study 19959684 — intervention group
Group type: COMPARATOR
Intervention: Alcohol history before diagnosis
Number of subjects: 264
Study 15793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg, twice daily)
Number of subjects: 19
Study 15793183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11778759 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent review committee (RC 1) evaluation
Number of subjects: 60
Study 11778759 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent review committee (RC 2) evaluation
Number of subjects: 60
Study 11778759 — intervention group
Group type: COMPARATOR
Intervention: Local investigator reports
Number of subjects: 60
Study 9435408 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (400 mg) for 5 days in any phase of the menstrual cycle
Number of subjects: 31
Study 9435408 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (100 or 200 mg) for 28 days starting on day 3 of the cycle
Number of subjects: 31
Study 8072187 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin (FOM) plus cefmetazole (CMZ)
Number of subjects: 54
Study 8072187 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin (FOM) plus flomoxef (FMOX)
Number of subjects: 54
Study 8072187 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) plus ceftazidime (CAZ) or ABK plus piperacillin (PIPC)
Number of subjects: 54
Study 3377925 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia S5‐T4
Number of subjects: 16
Study 3377925 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanaesthesia (NLA)
Number of subjects: 16
Study 12142560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (HD IL-2)
Number of subjects: 1
Study 12142560 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and plasmapheresis
Number of subjects: 1
Study 31913191 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-Knife Fistulotomy (NKF)
Number of subjects: 207
Study 31913191 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cannulation Method (CCM)
Number of subjects: 207
Study 29037926 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction clamp
Number of subjects: 85
Study 29037926 — intervention group
Group type: COMPARATOR
Intervention: Manual manipulation
Number of subjects: 85
Study 26968631 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interviewing intervention
Number of subjects: 200
Study 26968631 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 24219343 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing down the request for help on a request card
Number of subjects: 0
Study 24219343 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation without request card
Number of subjects: 0
Study 22955099 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal discussion
Number of subjects: 60
Study 22955099 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion plus information
Number of subjects: 60
Study 22955099 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interview plus information
Number of subjects: 60
Study 22955099 — intervention group
Group type: EXPERIMENTAL
Intervention: Action stage of readiness to change
Number of subjects: 60
Study 22955099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 60
Study 22955099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of depression
Number of subjects: 60
Study 22955099 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory and executive function, heavy preinjury alcohol use
Number of subjects: 60
Study 20207666 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to food temptations (pictures of food and real food)
Number of subjects: 0
Study 18533940 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Number of subjects: 30
Study 18533940 — intervention group
Group type: COMPARATOR
Intervention: 23-valent plain polysaccharide pneumococcal vaccine (23vPn)
Number of subjects: 30
Study 15983186 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric inpatient care
Number of subjects: 99
Study 15983186 — intervention group
Group type: COMPARATOR
Intervention: Geriatric outpatient care
Number of subjects: 99
Study 15983186 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study 12182217 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated weightlessness (supine body position)
Number of subjects: 65
Study 12182217 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-oxygenated for 60 min, first 10 min exercising)
Number of subjects: 65
Study 10485075 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese-DPDP
Number of subjects: 15
Study 10485075 — intervention group
Group type: COMPARATOR
Intervention: Gadolinium-DTPA
Number of subjects: 15
Study 8698787 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 96
Study 8698787 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 96
Study 8698787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 96
Study 8698787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 1750603 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intramuscular diamorphine
Number of subjects: 0
Study 1750603 — intervention group
Group type: COMPARATOR
Intervention: 5 mg epidural diamorphine
Number of subjects: 0
Study 1750603 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg epidural diamorphine
Number of subjects: 0
Study 1750603 — intervention group
Group type: COMPARATOR
Intervention: 5 mg epidural diamorphine with adrenaline 1/200,000
Number of subjects: 0
Study 1750603 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg epidural diamorphine with adrenaline 1/200,000
Number of subjects: 0
Study 1750603 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural diamorphine with adrenaline
Number of subjects: 0
Study 1750603 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg epidural diamorphine with adrenaline vs 2.5 mg with adrenaline
Number of subjects: 0
Study 7067925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single dose
Number of subjects: 100
Study 7067925 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 2 g single dose
Number of subjects: 100
Study 30450545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 225 mg
Number of subjects: 297
Study 30450545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 675 mg
Number of subjects: 297
Study 30127007 — intervention group
Group type: COMPARATOR
Intervention: CYD‐TDV vaccine
Number of subjects: 2
Study 28768076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.5 ATA
Number of subjects: 132
Study 28768076 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 132
Study 28768076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 2.0 ATA
Number of subjects: 132
Study 28768076 — intervention group
Group type: COMPARATOR
Intervention: Local care
Number of subjects: 132
Study 28768076 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (HOPPS study)
Number of subjects: 132
Study 28768076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.5 ATA (HOPPS study)
Number of subjects: 132
Study 23744292 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer navigation intervention
Number of subjects: 24
Study 23744292 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study 22353604 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ferric carboxymaltose and subcutaneous erythropoietin (EPOFE arm)
Number of subjects: 306
Study 22353604 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ferric carboxymaltose (FE arm)
Number of subjects: 306
Study 22353604 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo and subcutaneous placebo (PLACEBO arm)
Number of subjects: 306
Study 19645851 — intervention group
Group type: EXPERIMENTAL
Intervention: silver-loaded seaweed fiber T-shirts
Number of subjects: 37
Study 19645851 — intervention group
Group type: COMPARATOR
Intervention: cotton T-shirts
Number of subjects: 37
Study 19645851 — intervention group
Group type: EXPERIMENTAL
Intervention: silver-loaded seaweed fiber T-shirts and cotton T-shirts
Number of subjects: 37
Study 17624477 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (500 units)
Number of subjects: 29
Study 17624477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15823861 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin + ASA (Group A)
Number of subjects: 1600
Study 15823861 — intervention group
Group type: COMPARATOR
Intervention: Statin (Group B)
Number of subjects: 1600
Study 15823861 — intervention group
Group type: COMPARATOR
Intervention: ASA (Group C)
Number of subjects: 1600
Study 15823861 — intervention group
Group type: COMPARATOR
Intervention: No statin, no ASA (Group D)
Number of subjects: 1600
Study 12066485 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in prosthodontics
Number of subjects: 92
Study 9607867 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine
Number of subjects: 0
Study 9607867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9607867 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study 9607867 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 0
Study 7635993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 249
Study 7635993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 249
Study 7635993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 7635993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day and Methadone 65-80 mg
Number of subjects: 249
Study 7635993 — intervention group
Group type: EXPERIMENTAL
Intervention: Two visits/week
Number of subjects: 249
Study 7635993 — intervention group
Group type: EXPERIMENTAL
Intervention: Five visits/week
Number of subjects: 249
Study 2693560 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled bladder
Number of subjects: 142
Study 2693560 — intervention group
Group type: COMPARATOR
Intervention: Empty bladder
Number of subjects: 142
Study 576779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 56
Study 576779 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 56
Study 31219591 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of ACGD symptoms and molecular analysis of 'Candidatus Liberibacter africanus' (CLaf)
Number of subjects: 105
Study 31219591 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular characterization of pathogens
Number of subjects: 105
Study 31219591 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Candidatus Liberibacter asiaticus
Number of subjects: 105
Study 28631208 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt (MBTS)
Number of subjects: 261
Study 28631208 — intervention group
Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery shunt (RVPAS)
Number of subjects: 261
Study 28631208 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐Norwood
Number of subjects: 261
Study 28631208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐stage II
Number of subjects: 261
Study 28631208 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 months
Number of subjects: 261
Study 28631208 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PVF patterns
Number of subjects: 261
Study 26508834 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary kallidinogenase (UK) + conventional treatment
Number of subjects: 90
Study 26508834 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 90
Study 23846872 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6*1/*1 genotype
Number of subjects: 20
Study 23846872 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6*6 allele
Number of subjects: 20
Study 23846872 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed CYP2B6 proteins
Number of subjects: 20
Study 23846872 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6*6/*6 genotype
Number of subjects: 20
Study 21598901 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation and bilateral decompression via 1-sided paramedian approach (Group 1)
Number of subjects: 40
Study 21598901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pedicle screw fixation and bilateral decompression via bilateral paramedian approach (Group 2)
Number of subjects: 40
Study 21598901 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 40
Study 19420398 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity homework (30 minutes, 3 days a week for 12 weeks)
Number of subjects: 0
Study 19420398 — intervention group
Group type: COMPARATOR
Intervention: No homework
Number of subjects: 0
Study 19420398 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity homework
Number of subjects: 0
Study 16534040 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone care (n = 417)
Number of subjects: 837
Study 16534040 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 420)
Number of subjects: 837
Study 12753341 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2b alone for 48 weeks (R1: 42 patients)
Number of subjects: 297